Market Cap 396.51B
Revenue (ttm) 61.16B
Net Income (ttm) 4.23B
EPS (ttm) N/A
PE Ratio 22.87
Forward PE 15.66
Profit Margin 6.91%
Debt to Equity Ratio -26.45
Volume 6,830,300
Avg Vol 6,797,128
Day's Range N/A - N/A
Shares Out 1.77B
Stochastic %K 39%
Beta 0.35
Analysts Strong Sell
Price Target $246.15

Company Profile

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacture, commercialization, and sale of medicines and therapies worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, generalized pustular psoriasis, and pyoderma gangrenosum; Skyrizi to treat autoimmune diseases, erythrodermic psoriasis, generalized pustular psoriasis, and palmoplantar pustulosis; Rinvoq to treat inflammatory diseases; Imbruvica for...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 847 932 7900
Address:
1 North Waukegan Road, North Chicago, United States
GoodTidings
GoodTidings Feb. 21 at 1:54 PM
$SLS $MRK $ABBV $MRK $ABBV $PFE The observation of the day!!! I think if this pans out current BO valuations are missing an important valuation criteria!!! 🤔🤔🤔
0 · Reply
dewmoore
dewmoore Feb. 21 at 1:37 PM
$SLS Why $25 Billion is "Cheap" for Merck or Pfizer or Abbvie Let’s look at the "Buyout Boys" and why they might happily pay $50B! The Keytruda Killer: $MRK ’s Keytruda generates $30B to $35B PER YEAR. However, it hits a patent cliff in 2028. The "Sequel" Strategy: If Merck buys SELLAS, they don't just get a new drug; they get a way to protect their $30B/year franchise. By combining Keytruda with GPS, they can create a new, patented "Super-Drug" that extends their monopoly for another 10–15 years. $ABBV : AbbVie is a monster with a $500B war chest capacity through 2030. AbbVie's oncology division is currently "bleeding" (Imbruvica sales are down 23%); they desperately need a win like GPS. The Valuation : If an acquisition saves a $300B revenue stream over a decade, paying $40B or $50B for the key (SELLAS) is a bargain. This is why Pfizer paid $43B for Seagen—they weren't buying today's sales; they were buying the future of oncology. My 2027/2028 calls await you $MRK $ABBV $PFE
2 · Reply
dewmoore
dewmoore Feb. 21 at 1:21 PM
$SLS Per the FDA : STOP all of the fucking DD just release the damn drug NOW ! The FDA is moving fast AF! Hey $PFE $ABBV $MRK my Jan 2027/2028 calls patiently await your upcoming $100+ buyout battle! --New Cancer Drug Approval (Feb 19-20, 2026) The FDA has officially approved a new chemotherapy-free combination for patients with Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL). The Combo: Acalabrutinib (Calquence) plus Venetoclax (Venclexta). The Benefit: In clinical trials, the combo reduced the risk of disease progression or death by 35% ! Meanwhile our GPS drug is CRUSHING the comp - see ya at $100+ Hello Mr. FDA tell $SLS to stop this fucking trial now! LOL Happy Saturday!
0 · Reply
cubie
cubie Feb. 21 at 12:37 AM
$VNDA $JNJ $ABBV $BMY cubie teaches. lotta noob pumptards never heard of Abbvie, some outfit called Johnson & Johnson🤭, or Bristol Meyer😅🙄
1 · Reply
IN0V8
IN0V8 Feb. 20 at 8:52 PM
$ABBV Buy Berenberg raises target price to $275 from $270
0 · Reply
GrantHarvick
GrantHarvick Feb. 20 at 7:58 PM
$ABBV defensive growth still trending but monitoring for volume follow through
0 · Reply
dewmoore
dewmoore Feb. 20 at 5:08 PM
$SLS shouts out to my good guy over at Reddit -- he gave me a tip last night but I had to wait until he posted it --- well he's posted it! WTF is NIH??? Secret "CANCER" MEETINGS held this week: Why this is AIN'T normal: Federal law typically requires a 15-to-30-day notice. The NIH explicitly used "Exceptional Circumstances" to bypass these rules and hold these cancer meetings now.. LFG! Now that's NEW shit I haven't seen or heard all week ! Hey $PFE $ABBV $MRK my Jan. calls are waiting on that $100+ Hell fucking yeah he nailed that shit ! https://www.reddit.com/r/TheRaceTo10Million/comments/1ra0vbv/sls_the_secret_meetings_100_bidding_war_over/
3 · Reply
23hello23
23hello23 Feb. 20 at 5:04 PM
$ABBV $CRWV $CSAI $TPET you can close your eyes
1 · Reply
Teluride
Teluride Feb. 20 at 3:36 PM
$ABBV PT $275.00
0 · Reply
Oldpuck
Oldpuck Feb. 20 at 3:12 PM
$ABBV Who pulled the rug
0 · Reply
Latest News on ABBV
AbbVie Declares Quarterly Dividend

Feb 19, 2026, 9:37 AM EST - 2 days ago

AbbVie Declares Quarterly Dividend


AbbVie: Dominating Immunology While Building Oncology Upside

Feb 17, 2026, 1:11 AM EST - 4 days ago

AbbVie: Dominating Immunology While Building Oncology Upside


AbbVie sues US health agency over Botox price controls

Feb 11, 2026, 6:49 PM EST - 9 days ago

AbbVie sues US health agency over Botox price controls


Abbvie sues US health agency over Botox

Feb 11, 2026, 5:13 PM EST - 9 days ago

Abbvie sues US health agency over Botox


2 Urgent Sells And 2 No Brainer Dividend Buys

Feb 11, 2026, 4:06 PM EST - 9 days ago

2 Urgent Sells And 2 No Brainer Dividend Buys

AEP AMGN BMY ESS HASI HD PFE


Dividend Kings: No Ideal Buys In February's 57

Feb 10, 2026, 9:45 AM EST - 11 days ago

Dividend Kings: No Ideal Buys In February's 57

ABM ADP CWT FRT FTS HRL HTO


AbbVie: The Market Is Getting It Wrong

Feb 5, 2026, 8:52 AM EST - 16 days ago

AbbVie: The Market Is Getting It Wrong


AbbVie Inc. (ABBV) Q4 2025 Earnings Call Transcript

Feb 4, 2026, 1:20 PM EST - 16 days ago

AbbVie Inc. (ABBV) Q4 2025 Earnings Call Transcript


AbbVie Revenue Rises on Immunology Growth

Feb 4, 2026, 8:34 AM EST - 17 days ago

AbbVie Revenue Rises on Immunology Growth


Best Dividend Kings: January 2026

Jan 25, 2026, 10:11 PM EST - 26 days ago

Best Dividend Kings: January 2026

ABM ABT ADM ADP AWR BDX BKH


AbbVie plans to build out its presence in obesity market

Jan 14, 2026, 2:01 PM EST - 5 weeks ago

AbbVie plans to build out its presence in obesity market


Abbvie, US reach agreement to cut drug prices

Jan 12, 2026, 6:57 PM EST - 5 weeks ago

Abbvie, US reach agreement to cut drug prices


AbbVie, RemeGen partner on experimental solid tumor treatment

Jan 12, 2026, 7:39 AM EST - 5 weeks ago

AbbVie, RemeGen partner on experimental solid tumor treatment


Dividend Income: Lanny's November 2025 Summary

Jan 12, 2026, 5:12 AM EST - 5 weeks ago

Dividend Income: Lanny's November 2025 Summary

AFL CAT COF CVS CZNC EMR ETN


MoneyShow's Best Investment Ideas For 2026: Part 1

Jan 10, 2026, 9:30 AM EST - 6 weeks ago

MoneyShow's Best Investment Ideas For 2026: Part 1

ABR ACHR ARE ARES ASTS


AbbVie: The Dividend Does Not Lie

Jan 8, 2026, 12:07 PM EST - 6 weeks ago

AbbVie: The Dividend Does Not Lie


AbbVie Near Deal for Revolution Medicines

Jan 7, 2026, 2:48 PM EST - 6 weeks ago

AbbVie Near Deal for Revolution Medicines

RVMD


What Can Trigger A Breakout In Abbvie Stock?

Jan 6, 2026, 11:43 AM EST - 6 weeks ago

What Can Trigger A Breakout In Abbvie Stock?


GoodTidings
GoodTidings Feb. 21 at 1:54 PM
$SLS $MRK $ABBV $MRK $ABBV $PFE The observation of the day!!! I think if this pans out current BO valuations are missing an important valuation criteria!!! 🤔🤔🤔
0 · Reply
dewmoore
dewmoore Feb. 21 at 1:37 PM
$SLS Why $25 Billion is "Cheap" for Merck or Pfizer or Abbvie Let’s look at the "Buyout Boys" and why they might happily pay $50B! The Keytruda Killer: $MRK ’s Keytruda generates $30B to $35B PER YEAR. However, it hits a patent cliff in 2028. The "Sequel" Strategy: If Merck buys SELLAS, they don't just get a new drug; they get a way to protect their $30B/year franchise. By combining Keytruda with GPS, they can create a new, patented "Super-Drug" that extends their monopoly for another 10–15 years. $ABBV : AbbVie is a monster with a $500B war chest capacity through 2030. AbbVie's oncology division is currently "bleeding" (Imbruvica sales are down 23%); they desperately need a win like GPS. The Valuation : If an acquisition saves a $300B revenue stream over a decade, paying $40B or $50B for the key (SELLAS) is a bargain. This is why Pfizer paid $43B for Seagen—they weren't buying today's sales; they were buying the future of oncology. My 2027/2028 calls await you $MRK $ABBV $PFE
2 · Reply
dewmoore
dewmoore Feb. 21 at 1:21 PM
$SLS Per the FDA : STOP all of the fucking DD just release the damn drug NOW ! The FDA is moving fast AF! Hey $PFE $ABBV $MRK my Jan 2027/2028 calls patiently await your upcoming $100+ buyout battle! --New Cancer Drug Approval (Feb 19-20, 2026) The FDA has officially approved a new chemotherapy-free combination for patients with Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL). The Combo: Acalabrutinib (Calquence) plus Venetoclax (Venclexta). The Benefit: In clinical trials, the combo reduced the risk of disease progression or death by 35% ! Meanwhile our GPS drug is CRUSHING the comp - see ya at $100+ Hello Mr. FDA tell $SLS to stop this fucking trial now! LOL Happy Saturday!
0 · Reply
cubie
cubie Feb. 21 at 12:37 AM
$VNDA $JNJ $ABBV $BMY cubie teaches. lotta noob pumptards never heard of Abbvie, some outfit called Johnson & Johnson🤭, or Bristol Meyer😅🙄
1 · Reply
IN0V8
IN0V8 Feb. 20 at 8:52 PM
$ABBV Buy Berenberg raises target price to $275 from $270
0 · Reply
GrantHarvick
GrantHarvick Feb. 20 at 7:58 PM
$ABBV defensive growth still trending but monitoring for volume follow through
0 · Reply
dewmoore
dewmoore Feb. 20 at 5:08 PM
$SLS shouts out to my good guy over at Reddit -- he gave me a tip last night but I had to wait until he posted it --- well he's posted it! WTF is NIH??? Secret "CANCER" MEETINGS held this week: Why this is AIN'T normal: Federal law typically requires a 15-to-30-day notice. The NIH explicitly used "Exceptional Circumstances" to bypass these rules and hold these cancer meetings now.. LFG! Now that's NEW shit I haven't seen or heard all week ! Hey $PFE $ABBV $MRK my Jan. calls are waiting on that $100+ Hell fucking yeah he nailed that shit ! https://www.reddit.com/r/TheRaceTo10Million/comments/1ra0vbv/sls_the_secret_meetings_100_bidding_war_over/
3 · Reply
23hello23
23hello23 Feb. 20 at 5:04 PM
$ABBV $CRWV $CSAI $TPET you can close your eyes
1 · Reply
Teluride
Teluride Feb. 20 at 3:36 PM
$ABBV PT $275.00
0 · Reply
Oldpuck
Oldpuck Feb. 20 at 3:12 PM
$ABBV Who pulled the rug
0 · Reply
Stackdoe101
Stackdoe101 Feb. 20 at 2:04 PM
0 · Reply
ZacksResearch
ZacksResearch Feb. 20 at 1:25 PM
$ABBV riding its immunology giants — but can the momentum last? 💊 Skyrizi and Rinvoq drove more than 40% growth in 2025. The big question now: can these blockbusters power double-digit gains again in 2026? If they do, the top line story stays strong. Full outlook breakdown here 👉 https://www.zacks.com/stock/news/2872650/will-immunology-drugs-continue-to-drive-abbvies-top-line-in-2026?cid=sm-stocktwits-2-2872650-teaser-34344&ADID=SYND_STOCKTWITS_TWEET_2_2872650_TEASER_34344
0 · Reply
ZacksResearch
ZacksResearch Feb. 20 at 12:25 PM
$ABBV's immunology duo outpaces expectations — what's driving the growth? 🚀 💉 Skyrizi & Rinvoq combined revenues hit $26B, with Skyrizi up 50% YoY and Rinvoq up 39%, offsetting Humira's decline. 📈 Strong IBD market share & new indications fuel future sales projections. Discover the full growth story here 👉 https://www.zacks.com/stock/news/2872650/will-immunology-drugs-continue-to-drive-abbvies-top-line-in-2026?cid=sm-stocktwits-2-2872650-body-34343&ADID=SYND_STOCKTWITS_TWEET_2_2872650_BODY_34343
0 · Reply
WolfofTheCaribbean
WolfofTheCaribbean Feb. 20 at 10:46 AM
$CMPS $PFE $LLY $ABBV $JNJ must be scrambling to acquire this one before it’s too late. 14 billion recent acquisitions are just examples of how far it can go
0 · Reply
67X_ROI_Q1_2026
67X_ROI_Q1_2026 Feb. 20 at 7:52 AM
$SLS does everyone realize the IDMC UNBLINDED Actual Median Overall Survival Data and Immune Response date from the Interim Analysis of this ongoing Phase 3 Trial? You can see it on the Chart, since then SLS share price is up, market cap is up, cash is up to $100M from just $13M, Institutional Funds Invested is up to 174 from just 39… smart money knows and will continue rolling into position. $ABBV and $BMY also know, they know exactly how their drugs have failed in the AML Maintenance setting. shares are cheap - and phase 3 results are coming.
0 · Reply
67X_ROI_Q1_2026
67X_ROI_Q1_2026 Feb. 19 at 11:13 PM
$SLS $ABBV BAT FAILED
0 · Reply
HopefulCass
HopefulCass Feb. 19 at 10:25 PM
$VKTX Guys, Biolover is on Twitter talking about how $ABBV and $VKTX management just connected on LinkedIn. What the fuck am I reading here??????
1 · Reply
GoodTidings
GoodTidings Feb. 19 at 8:01 PM
$SLS $ABBV Statistically were already approved... We only need the official announcement... 😎😎😎
0 · Reply
GoodTidings
GoodTidings Feb. 19 at 8:00 PM
$SLS $ABBV I think it's a public secret now that GPS will be the standard of care for AML CR2 and AML CR1 soon... 😎😎😎
0 · Reply
67X_ROI_Q1_2026
67X_ROI_Q1_2026 Feb. 19 at 7:55 PM
$SLS $ABBV Gps is getting the FDA Green light to treat 12,500 AML CR2/3 patients Each year with an ad-infinite dosing regime. - Co Published min. Estimated Pricing $280K Per patient - Just AML CR2/3 $3.5B Year 1 - $5B in Year 2+ -- This alone is worth $20B to Big Pharma. Add in AML CR1 / and Post Transplant 40,000 Patients - Each Year @ $280K $11.2B in Year 1. $16.7B in Year 2. - Plus there are an estimated 100,000 AML Patients Currently in Remission - who will Immediately benefit from and be Eligible for GPs immunotherapy upon Approval. Gps will Set Records for patient uptake rates - 4x Survival advantage, near 100% Quality of Life, easy administration, high margin low cost manufacture, storage - Ip Rights into 2037, FDA/Eu Orphan and Fast Track - Rare Priority Review Designation. This Manipulated Share price is offering the Investment of a Lifetime. @yG19 you may want to update your model, i saw you used 3,000Cr2 patients and 6,000 Cr1 patients each year.
0 · Reply
ProfitFirst
ProfitFirst Feb. 19 at 5:25 PM
$ABBV $235 tomorrow
0 · Reply
V9RDPUMA
V9RDPUMA Feb. 19 at 4:59 PM
$ABBV WTF now?
0 · Reply